# Incident Response Template

## Purpose

Every production incident involving the 10-system ensemble must be documented using this template. Incidents include: accuracy drops >5%, system failures, security breaches, regulatory complaints, and user-reported issues.

---

## Incident Report Template

### 1. Incident Identification

| Field | Value |
|-------|-------|
| **Incident ID** | INC-XXXXXX (format: INC-MMDDYY, e.g., INC-042801) |
| **Severity Level** | CRITICAL / HIGH / MEDIUM / LOW |
| **Discovery Date/Time** | ISO 8601 timestamp (UTC), e.g., 2026-04-28T14:32:15Z |
| **Discovery Method** | Monitoring alert / User report / Batch validation / Manual review |
| **Assigned Investigator** | [Name, ML Engineer] |
| **Incident Commander** | [Name, ML Lead or CDO] |
| **Status** | OPEN / IN_INVESTIGATION / RESOLVED / CLOSED |

### 2. Impact Assessment

| Dimension | Value |
|-----------|-------|
| **Affected System(s)** | sys-001, sys-005, ... (list all) |
| **Accuracy Drop** | From X% to Y% (Z% total drop); in rolling 30-day window |
| **Impacted Traces** | [Number] traces affected out of [total] in period |
| **Impacted Users/Customers** | Segment: [e.g., "high-value accounts"], estimated [N] customers |
| **False Positive Rate** | [%] (approvals that should be rejections) |
| **False Negative Rate** | [%] (rejections that should be approvals) |
| **Customer Impact** | [Describe: missed opportunities, incorrect decisions, revenue impact] |
| **Regulatory Risk** | [High/Medium/Low] — does this violate SLA, fairness requirement, or compliance obligation? |

### 3. Escalation Decision

| Criterion | Met? | Action |
|-----------|------|--------|
| **Accuracy drop >5%** | Yes / No | If yes: WARNING escalation |
| **Accuracy drop >10%** | Yes / No | If yes: CRITICAL escalation → CTO + Risk Officer |
| **OOD detection >15%** | Yes / No | If yes: WARNING escalation → retrain immediately |
| **System agreement <6/10** | Yes / No | If yes: CRITICAL escalation → review ensemble config |
| **Fairness audit failure** | Yes / No | If yes: CRITICAL escalation → Compliance Officer |
| **Security incident** | Yes / No | If yes: CRITICAL escalation → CTO + Security |
| **Regulatory complaint** | Yes / No | If yes: CRITICAL escalation → Legal + CDO |

**Escalation Path**:
- **WARNING**: Notify ML Engineering Lead; prepare retraining plan
- **CRITICAL**: Notify CTO, Risk Officer, CDO, Compliance Officer within 4 hours

### 4. Timeline of Events

| Time | Event | Source | Owner |
|------|-------|--------|-------|
| 2026-04-28T14:32:15Z | Monitoring alert: accuracy drop detected | Dashboard | Platform Engineering |
| 2026-04-28T14:35:00Z | Incident created: INC-042801 | ML Engineering | Alice Chen |
| 2026-04-28T14:40:00Z | Incident Commander assigned | ML Lead | Bob Smith |
| 2026-04-28T15:00:00Z | Root cause investigation started | ML Engineering | Alice Chen |
| 2026-04-28T17:30:00Z | Root cause identified: [description] | ML Engineering | Alice Chen |
| 2026-04-29T09:00:00Z | Fix prepared and tested on dev | ML Engineering | Alice Chen |
| 2026-04-29T10:00:00Z | Data Governance Committee approved emergency retraining | CDO | Jane Smith |
| 2026-04-29T12:00:00Z | Canary deployment (5% traffic) | Platform Engineering | Mark Wu |
| 2026-04-30T12:00:00Z | Canary validation passed; full deployment ready | Platform Engineering | Mark Wu |
| 2026-05-07T12:00:00Z | Full deployment completed (100% traffic) | Platform Engineering | Mark Wu |
| 2026-05-14T10:00:00Z | Post-incident review completed | Incident Commander | Bob Smith |

### 5. Root Cause Analysis

#### 5.1 Description

[Detailed narrative of what went wrong. Include evidence from audit trails, test results, and data analysis.]

**Example**:
"On 2026-04-28, accuracy for sys-005 (XGBoost model) dropped from 96.2% to 91.1% (5.1% drop). Root cause: training data contained N=2,340 traces from a new customer segment (pharmaceutical industry) with features outside the original training distribution. The model had never seen pharma-specific terminology (e.g., 'FDA approval', 'clinical trial') and misclassified 340 traces. OOD detector did not flag these traces because Mahalanobis distance threshold was set to 2.5σ instead of 3.0σ (overfitting to baseline data)."

#### 5.2 Contributing Factors

- [ ] Data quality issue: [description]
- [ ] Model drift: concept drift / covariate shift
- [ ] Configuration error: threshold misconfigured, rule conflict unresolved
- [ ] Insufficient validation: test metrics passed but on unrepresentative data
- [ ] Dependency failure: upstream system changed behavior
- [ ] Security incident: weights tampered, audit trail corrupted
- [ ] Operational issue: deployment process not followed
- [ ] Other: [description]

#### 5.3 Why Monitoring Didn't Catch It Earlier

[Explain gaps in monitoring, alerts, or validation that allowed the incident to propagate to production.]

**Example**:
"Quarterly fairness audit (conducted 2026-04-01) used data from Jan–Mar (N=45,000 traces, 95% existing customer segments). New pharma customer segment data arrived in late April (after audit window) and was not separately validated. Weekly OOD checks did not flag the segment because checks were averaged across all systems; sys-005's OOD rate spike was masked by other systems' stability."

### 6. Fix Applied

#### 6.1 Type of Fix

- [ ] Retrain model(s) with corrected data
- [ ] Update rule set (symbolic system)
- [ ] Adjust hyperparameters / thresholds
- [ ] Fix OOD detection threshold
- [ ] Update data preprocessing
- [ ] Patch upstream dependency
- [ ] Fix deployment / rollback procedure
- [ ] Other: [description]

#### 6.2 Fix Details

[Describe the fix in technical detail. Include model version, hyperparameters, data changes, etc.]

**Example**:
"Retrained sys-005 (XGBoost) on 70% training data (5,600 traces) including 800 pharma traces (new segment underrepresented in original training set). Applied stratified K-fold cross-validation to ensure pharma segment fairly represented in each fold. Adjusted OOD detection threshold from 2.5σ to 3.0σ. New model: v1.6.0. Accuracy on test set: 96.8% (baseline: 96.2%, +0.6% vs. buggy v1.5.2)."

#### 6.3 Risk Assessment of Fix

| Risk | Probability | Mitigation |
|------|-------------|-----------|
| Fix introduces new bugs | Low | Tested on 1,600-trace test set; F1 scores validated |
| Fix breaks other systems | Low | Ensemble agreement tested (9.2/10, baseline 9.1/10) |
| Fix is incomplete | Low | Root cause fully understood; fix directly addresses cause |
| Fix degrades other metrics | Low | Precision, recall, fairness audited; all passed |

### 7. Validation and Testing

#### 7.1 Validation Checklist

| Check | Result | Evidence |
|-------|--------|----------|
| **Accuracy ≥95%** | PASS / FAIL | F1 = 96.8% on held-out 1,600 test traces |
| **Precision ≥92%** | PASS / FAIL | Precision = 97.1% per class |
| **Recall ≥92%** | PASS / FAIL | Recall = 96.5% macro average |
| **Fairness audit** | PASS / FAIL | Demographic parity: all protected attributes ≤3% disparity |
| **OOD detection** | PASS / FAIL | OOD validator rejects 96% of synthetic out-of-distribution traces |
| **Ensemble agreement ≥8/10** | PASS / FAIL | Average agreement = 9.2/10 on test set |
| **Adversarial test suite** | PASS / FAIL | All adversarial inputs correctly handled |
| **Audit trail integrity** | PASS / FAIL | All 1,600 test traces logged; signatures verified |
| **Regression test** | PASS / FAIL | Baseline cases (pre-incident data) still classified correctly; no performance degradation |

**Pass Criteria**: ALL checks must pass before proceeding to deployment.

#### 7.2 Canary Deployment (7 days)

| Metric | Threshold | Actual | Status |
|--------|-----------|--------|--------|
| **Canary duration** | 7 days | 168 hours (2026-04-29 12:00 → 2026-05-06 12:00) | PASS |
| **Traffic %** | 5% | 5% (1,200 requests/hour) | PASS |
| **Real-time accuracy** | ≥(baseline - 3%) = 88.1% | 96.5% (actual) | PASS |
| **System agreement** | ≥7/10 | 9.3/10 | PASS |
| **Incident count** | ≤2 | 0 incidents | PASS |
| **OOD detection rate** | ≤15% | 3.2% | PASS |

**Result**: PASS — Approved for full production deployment

#### 7.3 Post-Deployment Monitoring (7 days)

| Metric | Threshold | Status at Day 7 | Halt? |
|--------|-----------|---|---|
| **Accuracy** | ≥(baseline - 5%) = 91.2% | 96.6% (actual) | No |
| **System agreement** | ≥6/10 | 9.1/10 | No |
| **OOD detection** | ≤20% | 2.8% | No |
| **Incidents** | ≤5 | 0 | No |

**Result**: STABLE — Model remains deployed

### 8. Communication and Notification

#### 8.1 Stakeholders Notified

| Stakeholder | Role | Notification Time | Method |
|------------|------|------------------|--------|
| CTO | Executive escalation | 2026-04-28T15:00:00Z | Email + Slack |
| Chief Data Officer | Data governance | 2026-04-28T15:00:00Z | Email + Slack |
| Compliance Officer | Regulatory | 2026-04-28T15:00:00Z | Email |
| Legal | Risk | 2026-04-28T16:00:00Z | Email |
| Customer Success | Customer impact | 2026-04-28T17:00:00Z | Email |
| Affected Customers | Direct notification | 2026-04-28T18:00:00Z | Email (templated apology + remediation) |

#### 8.2 External Communications

- [ ] Regulatory notification required? [Yes / No] — If yes, filed by [date]
- [ ] Press release issued? [Yes / No] — If yes, approved by [CDO / Legal]
- [ ] Post-mortem published internally? [Yes / No] — If yes, link: [URL]

### 9. Prevention and Lessons Learned

#### 9.1 What Could Have Prevented This Incident?

| Prevention Measure | Implemented Before Incident? | Implementation Timeline |
|-------------------|------------------------------|------------------------|
| Separate OOD validation per customer segment | No | Q2 2026 (3 months) |
| Increase OOD detection threshold in validation | No | Completed (included in fix) |
| Monthly fairness audit (vs. quarterly) | No | Q2 2026 (implement in June) |
| Automated pharma-segment detection on data arrival | No | Q3 2026 (3 months) |
| Enhanced ensemble agreement monitoring per system | No | Q2 2026 (implement in May) |

#### 9.2 System Improvements

| Improvement | Owner | Target Date | Success Metric |
|-------------|-------|-------------|-----------------|
| Update OOD detection: per-segment validation | ML Engineering | 2026-05-31 | Rejects >95% of new segments |
| Monthly fairness audit (added to cadence) | Compliance | 2026-05-01 | 4 audits per year (vs. 1) |
| Segment-based canary: test new customer segments separately | Platform | 2026-06-30 | Separate alert thresholds per segment |
| Automated data quality checks on arrival | Data Engineering | 2026-05-31 | Flag deviations from baseline within 24h |

#### 9.3 Process Improvements

- [ ] Update RETRAINING_POLICY.md: Add per-segment OOD validation requirement
- [ ] Update MONITORING_DASHBOARD_SPEC.md: Add per-system agreement heatmap
- [ ] Update MODEL_CARD_TEMPLATE.md: Explicitly document OOD handling per system
- [ ] Update INCIDENT_RESPONSE_TEMPLATE.md: Add segment-based escalation criteria
- [ ] Update validation checklist: Add fairness check on new data segments

### 10. Sign-Off and Closure

| Role | Name | Date | Signature | Notes |
|------|------|------|-----------|-------|
| Investigator | Alice Chen | 2026-05-14 | A.Chen | Root cause confirmed; fix validated |
| Incident Commander | Bob Smith | 2026-05-14 | B.Smith | Post-incident review complete; lessons learned documented |
| ML Engineering Lead | Carol Davis | 2026-05-14 | C.Davis | No regressions; all systems stable |
| Data Governance Committee (CDO) | Jane Smith | 2026-05-14 | J.Smith | Incident closed; approved process improvements |
| Compliance Officer | Mark Wu | 2026-05-14 | M.Wu | No regulatory violations; documentation complete |

**Incident Status**: CLOSED (2026-05-14)

---

## Example: Complete Incident Report

### 1. Incident Identification

| Field | Value |
|-------|-------|
| **Incident ID** | INC-042801 |
| **Severity Level** | CRITICAL |
| **Discovery Date/Time** | 2026-04-28T14:32:15Z |
| **Discovery Method** | Monitoring alert (accuracy drop >5%) |
| **Assigned Investigator** | Alice Chen, Senior ML Engineer |
| **Incident Commander** | Bob Smith, ML Lead |
| **Status** | CLOSED |

### 2. Impact Assessment

| Dimension | Value |
|-----------|-------|
| **Affected System(s)** | sys-005 (XGBoost), sys-003 (Logistic Regression) |
| **Accuracy Drop** | sys-005: 96.2% → 91.1% (5.1% drop); sys-003: 95.8% → 91.4% (4.4% drop) |
| **Impacted Traces** | 2,340 traces (new pharma segment) out of 45,600 in past 30 days (5.1%) |
| **Impacted Users/Customers** | 1 pharmaceutical company customer; estimated 340 approval decisions affected |
| **False Positive Rate** | sys-005: 8.2% (vs. baseline 2.8%; +5.4 pp) |
| **False Negative Rate** | sys-005: 6.1% (vs. baseline 2.1%; +4.0 pp) |
| **Customer Impact** | Customer lost approval opportunity on 340 legitimate applications; estimated revenue impact $1.2M |
| **Regulatory Risk** | HIGH — SLA violation: accuracy drop >5% triggers escalation |

### 3. Escalation Decision

| Criterion | Met? | Action |
|-----------|------|--------|
| **Accuracy drop >5%** | YES | WARNING escalation |
| **Accuracy drop >10%** | NO | - |
| **OOD detection >15%** | YES | WARNING escalation → retrain immediately |
| **System agreement <6/10** | NO | 7.1/10 |
| **Fairness audit failure** | NO | Demographic parity ≤3% |
| **Security incident** | NO | - |
| **Regulatory complaint** | NO | - |

**Escalation**: CRITICAL (>5% accuracy drop + >15% OOD detection)  
**Notification**: CTO, CDO, Compliance Officer within 4 hours

### 4. Timeline of Events

| Time | Event | Source | Owner |
|------|-------|--------|-------|
| 2026-04-28T14:32:15Z | Monitoring alert: accuracy drop detected | Dashboard (real-time) | Platform Engineering |
| 2026-04-28T14:35:00Z | Incident created: INC-042801 | ML Dashboard | Alice Chen |
| 2026-04-28T14:40:00Z | Incident Commander assigned | Slack | Bob Smith |
| 2026-04-28T15:00:00Z | CTO, CDO, Compliance notified | Email | Bob Smith |
| 2026-04-28T15:30:00Z | Root cause investigation started | Zoom call | Alice Chen |
| 2026-04-28T17:30:00Z | Root cause identified: pharma segment OOD | Log analysis | Alice Chen |
| 2026-04-29T09:00:00Z | Fix implemented: retrain with pharma data | AutoML pipeline | Alice Chen |
| 2026-04-29T10:00:00Z | Data Governance Committee approved emergency retraining | Email approval | Jane Smith (CDO) |
| 2026-04-29T12:00:00Z | Canary deployment (5% traffic) | CI/CD pipeline | Mark Wu |
| 2026-04-30T12:00:00Z | Canary validation passed (7 days) | Dashboard | Mark Wu |
| 2026-05-07T12:00:00Z | Full deployment completed (100% traffic) | CI/CD pipeline | Mark Wu |
| 2026-05-14T10:00:00Z | Post-incident review completed | Zoom call | Bob Smith |

### 5. Root Cause Analysis

#### 5.1 Description

On 2026-04-28, accuracy for sys-005 (XGBoost model) dropped from 96.2% to 91.1% (5.1% drop) in the rolling 30-day window. Audit trail analysis revealed that N=2,340 traces from a new pharmaceutical industry customer arrived between 2026-04-20 and 2026-04-27. These traces contained industry-specific terminology (e.g., 'FDA approval', 'clinical trial', 'IND application') that was not represented in the original training data (collected Jan–Mar 2026; 95% existing customer segments, 0% pharma).

The XGBoost model (trained on baseline data without pharma examples) misclassified 340 of these 2,340 traces (14.5% error rate on new segment vs. 3.8% error rate on baseline). OOD detector did not flag the segment during automated checks because:

1. OOD threshold was configured at 2.5σ Mahalanobis distance (overfitted to baseline data)
2. Weekly OOD checks averaged across all 10 systems; sys-005's spike was masked by other systems' stability
3. New segment data arrived after the quarterly fairness audit (2026-04-01), which used Jan–Mar data only

#### 5.2 Contributing Factors

- [x] Data quality issue: New customer segment (pharma) with out-of-distribution features
- [x] Model drift: Covariate shift — new feature distributions (pharma-specific keywords) outside training range
- [ ] Configuration error: OOD threshold was overfitted; not system error per se
- [x] Insufficient validation: Quarterly fairness audit did not cover post-April data
- [ ] Dependency failure
- [ ] Security incident
- [ ] Operational issue: Deployment process was followed correctly
- [ ] Other

#### 5.3 Why Monitoring Didn't Catch It Earlier

Quarterly fairness audit (2026-04-01) used Jan–Mar data (N=45,000 traces, 95% existing segments). Pharma customer data arrived in late April (after audit window). Weekly OOD checks averaged across all 10 systems: sys-005's OOD rate spike (14.5% on pharma segment) was numerically masked when averaged with sys-001 (0.2%), sys-002 (0.3%), etc., resulting in ensemble-wide OOD rate of ~2.8% (below 15% alert threshold). **Lesson**: OOD detection must be per-system, not ensemble-wide.

### 6. Fix Applied

#### 6.1 Type of Fix

- [x] Retrain model(s) with corrected data (sys-005)
- [ ] Update rule set
- [x] Adjust hyperparameters / thresholds (OOD threshold 2.5σ → 3.0σ)
- [x] Fix OOD detection threshold
- [x] Update data preprocessing (added pharma-specific tokenization)
- [ ] Patch upstream dependency
- [ ] Fix deployment / rollback procedure
- [ ] Other

#### 6.2 Fix Details

1. **Retrained sys-005 (XGBoost)** with 70% training data (5,600 traces) including 800 pharma traces (stratified K-fold, 5 folds)
   - Version: 1.6.0 (from 1.5.2)
   - Hyperparameters: max_depth=5, learning_rate=0.05, n_estimators=200 (unchanged from baseline; no overfitting)
   - Accuracy on test set: 96.8% (baseline v1.5.2: 96.2%, +0.6 pp)
   - Precision (macro): 97.1% (baseline: 96.8%, +0.3 pp)
   - Recall (macro): 96.5% (baseline: 96.4%, +0.1 pp)
   - F1 (macro): 96.8% (baseline: 96.6%, +0.2 pp)

2. **Updated OOD detection threshold** from 2.5σ to 3.0σ
   - Rationale: 2.5σ was overfitted to baseline data; 3.0σ is standard industry practice
   - OOD validator rejects 96% of synthetic out-of-distribution traces (target: ≥95%, PASS)

3. **Updated data preprocessing** to recognize pharma-specific keywords
   - Added tokenization for compound terms ('FDA-approval', 'clinical-trial')
   - Does not break existing baseline tokenization; backward compatible

#### 6.3 Risk Assessment of Fix

| Risk | Probability | Mitigation |
|------|-------------|-----------|
| Fix introduces new bugs in sys-005 | Low (5%) | Tested on 1,600-trace held-out test set; F1 scores validated; regression test passed (baseline cases still work) |
| Fix breaks sys-003 (Logistic Regression) | Low (5%) | Ensemble agreement tested: 9.2/10 (baseline 9.1/10); sys-003 still performs well |
| Fix is incomplete (pharma not fully covered) | Low (2%) | Added 800 pharma traces to training; OOD detector rejects unknown pharma with 96% accuracy; confidence high |
| Fix degrades other metrics (fairness) | Low (3%) | Fairness audit passed: all protected attributes ≤3% disparity (baseline ≤2.5%, slight increase acceptable given segment addition) |

### 7. Validation and Testing

#### 7.1 Validation Checklist

| Check | Result | Evidence |
|-------|--------|----------|
| **Accuracy ≥95%** | PASS | F1 = 96.8% on held-out 1,600 test traces (includes 320 pharma) |
| **Precision ≥92%** | PASS | Precision = 97.1% (macro average, all classes) |
| **Recall ≥92%** | PASS | Recall = 96.5% (macro average, all classes) |
| **Fairness audit** | PASS | Demographic parity: gender ±2.1%, age ±1.8%, location ±3.0% (all ≤5% threshold) |
| **OOD detection** | PASS | OOD validator rejects 96% of synthetic out-of-distribution traces (target ≥95%) |
| **Ensemble agreement ≥8/10** | PASS | Average agreement = 9.2/10 on test set (sys-001, sys-002, ..., sys-010 all agree with sys-005 decision 92% of time) |
| **Adversarial test suite** | PASS | All adversarial inputs (typos, slang, domain shift) correctly handled; no regressions |
| **Audit trail integrity** | PASS | All 1,600 test traces logged in AUDIT_TRAIL_SCHEMA format; HMAC-SHA256 signatures verified; no tampering detected |
| **Regression test** | PASS | Baseline cases (pre-incident data from Jan–Mar) still classified correctly; accuracy on baseline unchanged (96.2%) |

**Pass Criteria**: ALL checks passed. Approved for deployment.

#### 7.2 Canary Deployment (7 days)

Canary period: 2026-04-29 12:00 UTC → 2026-05-06 12:00 UTC (168 hours)

| Metric | Threshold | Actual | Status |
|--------|-----------|--------|--------|
| **Canary duration** | 7 days | 7 days | PASS |
| **Traffic %** | 5% | 5% (1,200 req/hr) | PASS |
| **Real-time accuracy** | ≥88.1% (baseline - 3%) | 96.5% | PASS |
| **System agreement** | ≥7/10 | 9.3/10 | PASS |
| **Incident count** | ≤2 | 0 | PASS |
| **OOD detection rate** | ≤15% | 3.2% | PASS |

Result: PASS — Approved for full production deployment

#### 7.3 Post-Deployment Monitoring (7 days)

Post-deployment period: 2026-05-07 12:00 UTC → 2026-05-14 12:00 UTC (168 hours)

| Metric | Threshold (halt if exceeded) | Status at Day 7 | Halt? |
|--------|-----------|---|---|
| **Accuracy drop** | >5% | 96.6% (stable; baseline 96.2%) | No |
| **System agreement** | <6/10 | 9.1/10 | No |
| **OOD detection** | >20% | 2.8% | No |
| **Incidents** | >5 | 0 | No |

Result: STABLE — Model remains in production

### 8. Communication and Notification

#### 8.1 Stakeholders Notified

| Stakeholder | Role | Notification Time | Method |
|------------|------|------------------|--------|
| CTO (Technical Executive) | Executive escalation | 2026-04-28T15:00:00Z | Email + emergency Slack channel |
| Chief Data Officer | Data governance approval | 2026-04-28T15:00:00Z | Email + emergency Slack channel |
| Compliance Officer | Regulatory notification | 2026-04-28T15:00:00Z | Email + phone call |
| Legal (Risk Management) | Legal risk assessment | 2026-04-28T16:00:00Z | Email |
| Customer Success Lead | Customer impact & remediation | 2026-04-28T17:00:00Z | Email |
| Affected Pharma Customer | Direct notification | 2026-04-28T18:00:00Z | Email (apology + remediation offer) |
| All Customers (broadcast) | Transparency | 2026-04-28T19:00:00Z | Blog post + email (templated, non-identifying) |

#### 8.2 External Communications

- [x] Regulatory notification required? **Yes** — Filed to state data protection authority (2026-04-28)
- [x] Press release issued? **No** — Customer sensitivity; blog post only
- [x] Post-mortem published internally? **Yes** — Link: confluence.company.com/incidents/INC-042801

### 9. Prevention and Lessons Learned

#### 9.1 What Could Have Prevented This Incident?

| Prevention Measure | Implemented Before Incident? | Implementation Timeline |
|-------------------|------------------------------|------------------------|
| Separate OOD validation per customer segment | No | Q2 2026 (3 months) |
| Increase OOD detection threshold from 2.5σ to 3.0σ | No | Completed (included in fix) |
| Monthly fairness audit (vs. quarterly) | No | Q2 2026 (implement by 2026-05-31) |
| Automated segment-arrival detection on data ingest | No | Q3 2026 (3 months) |
| Enhanced ensemble agreement monitoring per system | No | Q2 2026 (implement by 2026-05-31) |

**Root prevention**: If OOD detection had been per-system (not ensemble-wide), sys-005's 14.5% OOD rate on pharma would have triggered alert immediately (threshold: 15%).

#### 9.2 System Improvements

| Improvement | Owner | Target Date | Success Metric |
|-------------|-------|-------------|-----------------|
| Per-system OOD monitoring dashboard | Platform Engineering | 2026-05-31 | Dashboard shows OOD rate for each of 10 systems independently |
| Monthly fairness audit cadence (up from quarterly) | Compliance Officer | 2026-05-01 | 4 audits per year (vs. 1) |
| Segment-based canary deployment | Platform Engineering | 2026-06-30 | New customer segments tested separately with 2-week validation |
| Automated data quality checks on data arrival | Data Engineering | 2026-05-31 | Flag ≥5% feature distribution deviation within 24h of ingest |

#### 9.3 Process Improvements

- [x] Update RETRAINING_POLICY.md: Add mandatory per-segment OOD validation before production acceptance
- [x] Update MONITORING_DASHBOARD_SPEC.md: Add per-system OOD rate heatmap; lower ensemble-wide threshold
- [x] Update MODEL_CARD_TEMPLATE.md: Require explicit documentation of known out-of-distribution segments per system
- [x] Update INCIDENT_RESPONSE_TEMPLATE.md: Add segment-based escalation criteria (>5% OOD rate per system = alert)
- [x] Add validation checklist: Per-system OOD validation on new data segments

### 10. Sign-Off and Closure

| Role | Name | Date | Signature | Notes |
|------|------|------|-----------|-------|
| Investigator | Alice Chen | 2026-05-14 | A.Chen (sig) | Root cause confirmed; fix validated on 1,600 test traces; no regressions |
| Incident Commander | Bob Smith | 2026-05-14 | B.Smith (sig) | Post-incident review complete; lessons learned documented; system improvements prioritized |
| ML Engineering Lead | Carol Davis | 2026-05-14 | C.Davis (sig) | All systems stable; ensemble agreement 9.1/10; ready for regular retraining cycle |
| Data Governance Committee (CDO) | Jane Smith | 2026-05-14 | J.Smith (sig) | Incident closed; approved process improvements; no regulatory violations |
| Compliance Officer | Mark Wu | 2026-05-14 | M.Wu (sig) | Regulatory notification filed; audit trail complete; no data loss |

**Incident Status**: CLOSED  
**Closure Date**: 2026-05-14T15:30:00Z  
**Follow-Up Review**: 2026-08-14 (3-month process improvement check)
